Literature DB >> 12011684

Vitreoretinal surgery for complications of branch retinal vein occlusion.

Ingrid U Scott1.   

Abstract

Branch retinal vein occlusion (BRVO) is second only to diabetic retinopathy as a cause of retinal vascular disease. Vision loss from BRVO may be associated with multiple causes, including macular edema, macular ischemia, foveal hemorrhage, vitreous hemorrhage, epiretinal membrane, and retinal detachment. The few published studies that report outcomes of pars plana vitrectomy for complications of BRVO consist only of case reports and small case series, limitations of which include small sample sizes and lack of comparison groups. Given the variable outcomes among patients with untreated BRVO, comparison groups are necessary for accurate evaluation of the efficacy of pars plana vitrectomy for BRVO.

Entities:  

Mesh:

Year:  2002        PMID: 12011684     DOI: 10.1097/00055735-200206000-00005

Source DB:  PubMed          Journal:  Curr Opin Ophthalmol        ISSN: 1040-8738            Impact factor:   3.761


  3 in total

1.  Investigation of gold-coated bare fiber probe for in situ intra-vitreous coherence domain optical imaging and sensing.

Authors:  J-H Han; I K Ilev; D-H Kim; C G Song; J U Kang
Journal:  Appl Phys B       Date:  2010-06-01       Impact factor: 2.070

2.  Management of branch retinal vein occlusion with vitrectomy and arteriovenous adventitial sheathotomy, the possible role of surgical posterior vitreous detachment.

Authors:  Jérôme Charbonnel; Agnès Glacet-Bernard; Jean-François Korobelnik; Emilienne Nyouma-Moune; Constantin J Pournaras; Joseph Colin; Gabriel Coscas; Gisèle Soubrane
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-12-18       Impact factor: 3.117

3.  Effect of prophylactic 360° laser treatment for prevention of retinal detachment after phacovitrectomy: (Prophylactic 360° laser treatment for prevention of retinal detachment).

Authors:  Takeshi Iwase; Young-Joon Jo; Brian C Oveson
Journal:  BMC Ophthalmol       Date:  2013-12-10       Impact factor: 2.209

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.